ReviewCureus2021
Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications.
Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Drug-induced regeneration of pancreatic beta cells: An approach to cellular therapeutic targets.Cell regeneration (London, England) · 2025Review
- Mesenchymal stem cell-based therapy for type 1 & 2 diabetes mellitus patients: a systematic review and meta-analysis of randomized controlled trials.Diabetology & metabolic syndrome · 2025Article
- Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.International journal of surgery (London, England) · 2024Review
- The role of fetal pancreatic islet cell transplantation in the treatment of type 2 diabetes mellitus.Journal of diabetes and metabolic disorders · 2024Article
- Comprehensive insights into mechanism of nanotoxicity, assessment methods and regulatory challenges of nanomedicines.Discover nano · 2024Review
- Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs.Animal models and experimental medicine · 2024Review
- Mesenchymal Stem Cell Transplantation in Type 1 Diabetes Treatment: Current Advances and Future Opportunity.Current stem cell research & therapy · 2024Review
- Successful lifestyle modifications may underlie umbilical cord-mesenchymal stromal cell effects in type 2 diabetes mellitus.World journal of diabetes · 2023Article
- The Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes- A Literature Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Stem Cell-Based Therapies: What Interventional Radiologists Need to Know.Seminars in interventional radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a serious and common chronic disease with high morbidity and mortality rates. Recently, stem cell-based therapy has shown considerable promise as a future therapeutic modality for DM. This review aims to summarize the types of stem cells that have the most successful evidence in treating type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), and also to assess the safety and efficacy of different types of stem cells in the treatment of DM. PubMed, MEDLINE, and PubMed Central databases were searched up to October 15, 2020, using medical subject heading (MeSH) terms. After application of inclusion criteria and exclusion criteria, 10 studies were included in our final review: six T1DM studies including 120 patients, and four T2DM studies including 65 patients. Our data showed that autologous and allogeneic stem cell therapy is a relatively safe and effective method for selected individuals with DM. The best therapeutic outcome was achieved by transplantation of bone marrow hemopoietic stem cells (BM-HSCs) for T1DM and bone marrow mononuclear cells (BM-MNCs) along with mesenchymal stromal cells (MSCs) for T2DM. However, patients with DKA are not a good candidate for stem cell transplantation. Further rigorous experiments are needed in order to be able to establish stem cell-based therapies as the future standard of care for treating DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.